FIP in Cats: The Welfare Transformation of a Fatal Disease
FIP Overview
Feline infectious peritonitis (FIP) is caused by virulent mutations of feline coronavirus (FCoV) that develop in individual cats. Approximately 10% of cats infected with endemic FCoV develop FIP. Mutations allow the virus to replicate in macrophages, causing systemic vasculitis and granulomatous inflammation. Forms: effusive ('wet' FIP — accumulation of fluid in body cavities); non-effusive ('dry' FIP — granulomas in organs); or mixed. It was universally fatal until the development of antiviral drugs.
The Antiviral Treatment Revolution
GS-441524 (a nucleoside analogue related to remdesivir) and its prodrug GS-5734 (remdesivir) have transformed FIP from a fatal disease to a manageable, often curable condition. Clinical trials and widespread clinical use show remission rates of 85-90%+ in cats treated for 12 weeks with appropriate GS-441524 doses. The drug is now licensed in some countries (molnupiravir/GS-441524 formulations); access via veterinary prescription has improved dramatically since 2021-2023. This is one of the most significant recent advances in feline medicine welfare.
Diagnosis and Early Treatment
Early diagnosis maximises treatment success. FIP diagnosis: Rivalta test (fluid); high effusion protein and low albumin:globulin ratio; alpha-1-acid glycoprotein (AGP) elevation; PCR of effusion or tissue; specific FCoV spike protein PCR; and immunostaining of biopsies. The A92E mutation in the FCoV spike protein is specifically associated with virulent FIP virus. Given that early treatment gives better outcomes, veterinary teams should have a low threshold for FIP testing in young cats with consistent clinical signs.
Treatment Protocol and Welfare
Typical treatment: 12 weeks of GS-441524 subcutaneous injection or oral tablet at appropriate mg/kg dosing based on form (effusive requires lower dose initially; neurological/ocular FIP requires higher dose; non-effusive typically requires higher dose throughout). Monitoring: weekly then monthly clinical assessment, repeated measurement of key blood markers (lymphocyte count, albumin, AGP). Most cats show dramatic clinical improvement within 1-2 weeks. Treatment is not without welfare costs: daily injections cause injection site reactions in some cats.
Cost and Access Welfare Challenges
FIP treatment remains expensive (typically £2,000-£8,000+ per cat for the full treatment course depending on dose and form), creating significant welfare inequity: cats of owners who cannot afford treatment may die of a now-treatable disease. Access to licensed GS-441524 products varies by country. Veterinary practices should provide honest prognostic counselling; early discussion of costs allows owners to make informed decisions. Charity support and veterinary payment plans can improve access. The welfare inequality created by expensive treatments is an ethical issue for the profession.